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ABSTRACT: Introduction: There are no validated, practical, and
quantitative measures of disease severity in Lambert-Eaton
myasthenia (LEM). Methods: Data from the Effectiveness of
3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
(DAPPER) trial were analyzed to assess triple timed up-and-go
(3TUG) reproducibility and relationships between 3TUG times and
other measures of LEM severity. Results: The coverage probability
technique showed ≥0.90 probability for an acceptable 3TUG differ-
ence of ≤0.2, indicating that it is reproducible in LEM patients. The
correlation between 3TUG times and lower extremity function scores
was significant in subjects who continued and in those who were
withdrawn from 3,4-diaminopyridine free base. Worsening patient-
reported Weakness Self-Assessment Scale and Investigator
Assessment of Treatment Effect scores corresponded with prolonga-
tion of 3TUG times. Discussion: The 3TUG is reproducible, dem-
onstrates construct validity for assessment of lower extremity
function in LEM patients, and correlates with changes in patient
and physician assessments. These findings, along with prior
reliability studies, indicate 3TUG is a valid measure of disease
severity in LEM.
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INTRODUCTION
Lambert-Eaton myasthenia (LEM) is a rare and
debilitating disorder of neuromuscular transmission
caused by autoantibodies to the P/Q-type voltage-
gated calcium channels (VGCCs) of the presynaptic
neuromuscular junction.1 Patients typically present
with weakness in the shoulder, hip, and thigh mus-
cles2 and autonomic dysfunction.3 Dysphagia and
respiratory failure4 can be prominent in some
patients. The decline in lower extremity strength
leads to impaired mobility5 and poor quality of life.6
Several single-center studies7–11 have demon-
strated improvement in LEM-associated weakness
after administration of the potassium channel
antagonist12–14 3,4-diaminopyridine free base (DAP).
Previous treatment trials of DAP in LEM have used
change in strength of selected muscles,11 the quanti-
tative myasthenia gravis (QMG) score,12,13 or myo-
metry8,11 as primary outcome measures, with
compound muscle action potential (CMAP)
amplitude8,11–13 as a secondary outcome measure in
some trials. Autonomic function testing, patients’
subjective symptoms, and physicians’ disease classifi-
cation have also been used as measures of disease
severity in LEM trials. None of these measures have
been validated in LEM, and others, including the
QMG, do not measure important causes of LEM-
related disability, such as proximal lower extremity
weakness and diminished mobility. Electrodiagnostic
studies are time-consuming and the availability of
some techniques is limited to specialized centers,
making them impractical as routine clinical mea-
sures of disease severity.
An optimal outcome measure for LEM should ful-
fill the basic requirements proposed by Hobart
et al,15 and that it be clinically practical and
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scientifically sound on the basis of validity, reliability,
and responsiveness.
The timed up-and-go (TUG) test16 is a simple objec-
tive measure of mobility that has been validated primarily
in geriatric populations with parkinsonism17,18 and
impaired cognition.19,20 It requires the patient to rise up
from the seat of a straight-backed armchair, walk 3 meters
at a normal pace, turn around, walk back to the chair,
turn, and sit back down. A variation of this test, the triple
timed up-and-go (3TUG) test, requires 3 repetitions
(laps), and assesses the lower extremity weakness and
fatigue or facilitation characteristic of LEM. The 3TUG
has been demonstrated to have excellent test-retest
reproducibility and interrater reliability in patients with
non-LEM neuromuscular disorders, but has not been
fully validated in LEM.
This study was designed to further validate the
3TUG in LEM patients by confirming test-retest
reproducibility and interrater reliability, establishing
construct validity through correlation with other
measures of LEM-specific disability, and assessing its
responsiveness to patient- and provider-reported
measures of disease severity.
METHODS
This study was a secondary analysis of data from the Effectiveness
of 3,4-Diaminopyridine in Lambert–Eaton Myasthenic Syndrome
(DAPPER) clinical trial, a double-blind, placebo-controlled with-
drawal study of DAP in patients with LEM (NCT01511978).22
The trial consisted of 4 stages (refer to Figure S1 in the Supple-
mentary Material online): Acclimation (0.5 day); Baseline
(2 days); Withdrawal (up to 3.5 days); and DAP Reinstitution
(0.5-2 days). Data from participants who completed at least the
acclimation and baseline observation stages were included in this
analysis. Participants were randomized to receive DAP or placebo
as per home schedules. Time-points for non-3TUG measures
(see Figure S1 online) were determined based on when they were
performed before randomization or during withdrawal, and were
matched with the closest 3TUG time. Lower Extremity Function
Scale (LEFS) scores were obtained during Acclimation (day 0)
and again at the end ofWithdrawal or time of early advancement;
all other baseline measurements were obtained during Baseline
(day 2).
Oversight. The institutional review board of the Duke Uni-
versity Health System exempted this study (Pro00083458)
from review.
Outcome measures. The 3TUG was performed before and
after the first DAP doses of the afternoon and evening with
4 test times daily during the Acclimation stage and 6 times
daily (including before and after first morning dose) during
the Baseline and Withdrawal stages.
CMAPs were measured in the muscle determined to be
most responsive to DAP during the Acclimation stage and
were reviewed for quality by a blinded observer (see Table S1
online). CMAP amplitude was measured before and after the
first doses of the morning and afternoon during the Baseline
and Withdrawal stages.
The LEFS (see Figure S2 online) is a 20-item patient-
reported outcome measure commonly used to assess mobility
in patients with orthopedic conditions.23 The best possible
score is 80, and a change of 9 points indicates a clinically mean-
ingful change in functional ability. Although this tool has not
been used in patients with LEM, the predominant lower extrem-
ity and hip-girdle weakness in LEM is consistent with symptoms
experienced by patients with musculoskeletal problems.
The Weakness Self-Assessment Scale (W-SAS) is a secondary
efficacy measure created by the DAPPER trial sponsor (see
Figure S3 online). It features 7 categories with numerical values
that allow a participant to rank weakness along a continuum from
“Much much weaker” (-3) to “Much much stronger” (+3). The
W-SAS was performed 2 hours after the first DAP doses of the
afternoon and evening with 2 test times daily during Baseline and
3 times daily (including first morning dose) during Withdrawal.
The Investigator Assessment of Treatment Effect is a 5-item
categorical scale created by the DAPPER trial sponsor (see
Figure S4 online). It was performed by a study-blind investigator
to assess overall disease severity at the conclusion of withdrawal
or at the time of early advancement. Participants were assessed
along a continuum from “Much worse than during baseline”
(0) to “Much improved from baseline” (4).
Statistical analysis. Reproducibility and reliability analyses
were performed using data from participants who completed
the Acclimation and Baseline stages. The other analyses
included only randomized participants. Because the goal of
this validation study was to evaluate 3TUG performance over
time in participants who are clinically stable (continuous
DAP) and clinically changing (controlled DAP withdrawal),
between-group comparisons of outcome measures for those
who continued DAP and those who were withdrawn from DAP
were not performed; these have been reported previously.22
All analyses were performed using a percentage change from
Baseline rather than the absolute values at the prespecified
time-points. Data were analyzed using SAS version 9.4 (SAS
Institute, Cary, North Carolina).
Test-retest reproducibility and interrater reliability of
3TUG. Time-matched 3TUG times recorded by the same
onsite observer for the same participant on 2 consecutive days
(Figure 1) were analyzed to assess test-retest reproducibility.
Participants continued their home doses of DAP during these
stages, and only data from participants with values for both
time-points were included. Agreement between 2 observations
of the same 3TUG was determined by comparing 3TUG times
recorded by an onsite observer and a remote observer who
viewed videotaped 3TUGs. Only participants with observations
by 2 different observers were included (n = 46). The coverage
probability (CP) method was used to assess agreement
between paired observations.24 A CP value is the probability
that the ratio between paired observations falls within a pre-
established range: it is calculated by dividing the number of
observed ratios within the acceptable range by the total num-
ber of comparisons. For this study, it was established a priori
that agreement would be demonstrated by a CP ≥0.90. Point
estimates and a 95% CIs for the CP were calculated for an
acceptable difference of ≤20%. A sensitivity analysis for an
acceptable difference of ≤10% was also performed. Bland-
Altman plots were constructed.
3TUG times vs CMAP amplitudes. The association between
change in 3TUG time recorded by an onsite observer and change
in time-matched CMAP by treatment group was assessed using
data from subjects with both non-missing postdose 3TUG times
and CMAP amplitudes for the first afternoon dose at baseline and
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during each day of the withdrawal phase. Percent change in
3TUG time and CMAP amplitude were calculated using the fol-
lowing formula:
Postdose withdrawal−Postdose baselineð Þ= Postdose baselineð Þ½ × 100
Descriptive statistics for the mean absolute and percentage
change in 3TUG time and CMAP amplitude were calculated.
A multivariable linear regression was fit to the data by ran-
domization group using the prespecified model:
ΔCMAPi =Δ3TUGi + Pyridostigmine bromide PBð Þ +Age +Assistive device
Only statistically significant (P < .05) adjustment variables
were reported in the final model due to risk of overfitting with
the small sample size. A simplified univariate linear regression
was reported as: ΔCMAPi = Δ3TUGi.
3TUG times vs LEFS scores. The association between
change in 3TUG time recorded by an onsite observer and
change in LEFS scores by treatment group was assessed using
data from participants with time-matched postdose 3TUG
times and LEFS scores from baseline and at the end of With-
drawal. Percent change in 3TUG time was calculated using
the following formula:
Withdrawal value−Baseline valueð Þ= Baseline valueð Þ½ × 100
Raw change in the LEFS score was calculated by subtracting
the Baseline value from the Withdrawal value.
Descriptive statistics were calculated for the change in
3TUG time and LEFS score at each time-point. Spearman cor-
relations between the time-matched 3TUG time and LEFS
scores and percent change in 3TUG time and raw change in
LEFS scores were determined.
3TUG times vs W-SAS. The association between change in
3TUG time and change in W-SAS score was assessed by comparing
the last available time-matched 3TUG time and W-SAS score in the
Withdrawal stage (days 4 or 5) and the last available time-matched
W-SAS and 3TUG time during Baseline stage (day 2). Descriptive
statistics were calculated for the percent change in 3TUG time and
change in numerical W-SAS score for each randomization group.
3TUG times vs Investigator Assessment of Treatment
Effect. The association between change in 3TUG time
recorded by an onsite observer and overall Investigator Assess-
ment was determined by comparing the change in 3TUG time
to the Investigator Assessment at the end of withdrawal. Only
participants with documented values for both 3TUG and the
investigator assessment at the end of Withdrawal were
included in the analysis.
RESULTS
Test-retest reproducibility of 3TUG. Forty-six pairs of
observations recorded by onsite observers were ana-
lyzed (Table 1). The CP for agreement in time-
matched observations on consecutive days is 0.93
(95% CI, 0.82-0.99) for an acceptable range of
≤20%, and 0.67 (95% CI, 0.54-0.81) for an accept-
able range of ≤10% (see Figure S5 online).
FIGURE 1. Percent change in CMAP amplitude vs percent
change in 3TUG time during Withdrawal (stage II). CMAP
amplitude and 3TUG time are standardized to Baseline (day 2).
Lines of best fit show an association between percent change in
CMAP amplitude and percent change in 3TUG time as DAP is
progressively withdrawn on days 3 (A) and 4 (B). The association
is not apparent on day 5 (C). 3TUG, triple timed up-and-go test;
CMAP, compound muscle action potential; DAP,
3,4-diaminopyridine free base




Test 1 Test 2 Observer 1 Observer 2
Mean 3TUG 10.2 10.0 10.0 10.0
SD 2.9 2.8 2.8 2.9




Abbreviation: 3TUG, triple timed up-and-go test.
*Postdose following the first afternoon dose on day 0 and day 1.
†Postdose following the first afternoon dose on day 1. Forty-six paired
observations are represented in each analysis.
294 Validation of 3TUG MUSCLE & NERVE September 2019
Interrater reliability of 3TUG. Forty-six pairs of obser-
vations from Baseline were analyzed (Table 1). The
CP for agreement between unblinded and blinded
observers for the same 3TUG test was 1.00 (95% CI,
0.92-1.00) for an acceptable range of ≤20%, and 1.00
(95% CI, 0.92-1.00) for an acceptable range of ≤10%
(see Figure S6 online).
3TUG time vs CMAP amplitude. Between baseline
and the last postdose CMAP of the Withdrawal
period (study day 5 or early advancement), 3TUG
times increased by a mean of 1.5% (95% CI, −0.4 to
0.6) in those who continued DAP (n = 8) and by a
mean of 32.9% (95% CI, 16.4-49.3) in those who
were withdrawn from DAP (n = 8) (see Table S2
online). In this same time period, the CMAP
decreased by a mean of −6.9% (95% CI, −21.2 to
7.5) in those who continued DAP and by a mean of
−40.9 (-3.4 mV; 95% CI, −60.5 to −21.3) in those
who were withdrawn from DAP (see Table S3
online). Scatterplots with a line of best fit suggest a
trend of decreasing CMAPs with increasing 3TUG
times (Figure 1). Linear regression revealed a sig-
nificant (P < .01) association between 3TUG time
and CMAP amplitude during the second day of the
Withdrawal stage (study day 4) in those who were
withdrawn from DAP; in these subjects, an increase
of 1% in 3TUG time was associated with a −1.05%
(95% CI, −1.52 to −0.57) change in CMAP ampli-
tude (Table 2). This association was not significant
at Baseline or at the end of Withdrawal (study day
5) in either group.
3TUG times vs LEFS scores. Between baseline and
the LEFS at the end of the withdrawal stage, the
3TUG time decreased by a mean of 1.9% (0.1 sec-
ond) in the group that continued DAP (n = 13) and
increased by 126.3% (14.4 seconds) in the group
that was withdrawn from DAP (n = 15). LEFS scores
decreased by a mean of 2 points in the continued
treatment group and decreased by 24 points in the
group that was withdrawn from DAP. Spearman
correlation showed a strong negative correlation
between the 3TUG time and the total LEFS score
before reinstitution of DAP in the continued DAP
group (r = -0.64, P = .02) and in those who were with-
drawn from DAP (r = −0.64, P = .01).
3TUG times vs W-SAS. Between Baseline and the
end of the Withdrawal stage, the 3TUG time
increased by a mean of 2.1% (0.2 second) in the
group that continued DAP (n = 13) and by 81.5%
(9.3 seconds) in the group that was withdrawn from
DAP (n = 16). Among those withdrawn from DAP,
an increase in 3TUG time was associated with a
greater decline in W-SAS score (Figure 2A). Worsen-
ing of at least 3 W-SAS points corresponded with a
mean prolongation of ≥73.6% of 3TUG time. Across
both treatment groups, 3 of 11 (27.3%) participants
who reported feeling “Much, much weaker” were
unable to perform the 3TUG.
3TUG times vs Investigator Assessment of Treatment
Effect. Blinded investigators assessed participants at
baseline and at the end of the withdrawal period.
Participants who were graded “Much worse” than at
baseline had a mean increase of ≥94.3% in their
3TUG time and all were withdrawn from DAP
(n = 18); no participants who continued DAP
(n = 13) were rated as “Much worse” (Figure 2B).
Across both treatment groups, 3TUG times deterio-
rated by ≥30% in 81.3% (13 of 16) of participants
who were rated as “Somewhat worse” (4 of 16) or
“Much worse” (12 of 16). Among those rated as
“Much worse,” 91.7% (11 of 12) had a ≥ 30% deteri-
oration in 3TUG. A total of 3 participants who were
rated as “Much worse” were not able to perform the
3TUG. No participants were reported as “Somewhat
better” or “Much better.”
DISCUSSION
The results of this study demonstrate that the 3TUG
has both excellent reproducibility and interrater reli-
ability in a population of LEM patients on stable
Table 2. Association between change from baseline postdose CMAP amplitude and change from baseline postdose 3TUG*
Continuous DAP Withdrew from DAP
Effect estimate (95% CI) P value Effect estimate (95% CI) P value
Day 3† -0.70 (-3.33 to 1.92) 0.55 -0.01 (-2.20 to 2.18) 0.99
Day 4‡ -0.43 (-1.65 to 0.79) 0.43 -1.05 (-1.52 to -0.57) <0.01
Day 5§ 0.32 (-1.69 to 2.32) 0.71 -0.52 (−1.59 to 0.56) 0.29
Abbreviations: 3TUG, triple timed up-and-go test; CMAP, compound muscle action potential; DAP, 3,4-diaminopyridine free base.
Only 3TUG-CMAP pairs with CMAPs considered acceptable by the study-blind reviewer were included in the analysis for each day.
*ΔCMAPi = Δ3TUGi.
†Continued on DAP, n = 10; withdrawn from DAP, n = 14.
‡Continued on DAP, n = 9; withdrawn from DAP, n = 12.
§Continued on DAP, n = 8; withdrawn from DAP, n = 8.
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therapy and has content and face validity for the
assessment of lower extremity dysfunction. The DAP-
PER trial demonstrated that the W-SAS accurately
captures patient perceptions of weakness,22 and analy-
sis of the 3TUG has revealed that prolongation of
3TUG times corresponds with declines in W-SAS
scores. In addition, deteriorations in 3TUG times are
congruent with worsening, as assessed by blinded
investigators. Together, these results indicate that the
3TUG is responsive to patient- and clinician-reported
changes in disease severity. This offers an advantage
over electrophysiological measures because it can be
performed without special equipment and technical
training.
Although there is no “gold standard” of LEM
severity for comparison, the 3TUG can be compared
with other measures of lower extremity function and
mobility, such as the validated LEFS, with which it
correlated well at the end of the withdrawal period,
both in participants who continued DAP and in
those who were withdrawn from DAP. Earlier work23
has established the clinically meaningful change in
LEFS score to be 9 points, consistent with observa-
tions in the DAPPER LEM participants who were
withdrawn from DAP (mean, −22; range, −33 to −8),
providing content validity of the 3TUG as an assess-
ment of lower extremity function.
The present study has several limitations related to
the comparator instruments and small sample sizes.
The effect estimate of CMAP amplitude and 3TUG
times was significant only in the middle of the with-
drawal period (study day 4) for those who were with-
drawn from DAP. This was unexpected because earlier
reports demonstrated increases in CMAP amplitude
after DAP administration.10,11,14,25 Several factors may
have played a role in these inconsistent results, among
FIGURE 2. (A) Number of responders by change in W-SAS score. The numerical value represents the mean percent change in 3TUG
time for each W-SAS score. (B) Number of responders by change in investigator assessment of overall treatment effect. The numerical
value represents the mean percent change in 3TUG time for each Investigator Assessment category. 3TUG, triple timed up-and-go test;
DAP, 3,4-diaminopyridine free base; PI, principal investigator; W-SAS, Weakness Self-Assessment Scale
296 Validation of 3TUG MUSCLE & NERVE September 2019
them the small number of participants, particularly at
the end of withdrawal, due to rescue, and differences
in the CMAP technique used at the different study
sites.26–28 Indeed, CMAPs from only 10 of 12 (83%) of
participants who continued DAP met the predeter-
mined criteria for acceptability (see Table S3 online)
on the first day of withdrawal (study day 3) and the
number of acceptable CMAP studies was lower at each
subsequent assessment. This pattern was also observed
in the group withdrawn from DAP: only 14 of
18 (78%) participants had acceptable CMAP studies
on study day 3, and the number of acceptable CMAP
studies declined at each subsequent assessment. These
findings highlight the need for careful attention to the
technical aspects of performing electrodiagnostic mea-
sures, and the potential limitations of using CMAP
amplitudes in multicenter clinical trials unless rigorous
training is employed. These concerns are shared with
regard to other electrodiagnostic measures, as recently
highlighted in an editorial on the use of motor unit
number index (MUNIX) in clinical trials.29 An alterna-
tive methodology using longitudinal analysis strategies,
such as mixed-effects modeling, in an adequately pow-
ered study, may provide a more accurate assessment of
the relationship between pre- and postdose 3TUG
times and CMAP amplitudes, and could also assess clin-
ically meaningful covariates such as age, use of pyridos-
tigmine, and assistive devices.
Although the CP for agreement in the test-retest
reproducibility of the 3TUG was 0.93 for an accept-
able range of ≤20%, the CP for an acceptable range
of ≤10% was 0.67. This suggests the possibility of
skew and dispersion in the data. The original DAP-
PER analysis did not report data from day 0 because
of concerns that fatigue due to travel could have an
unpredictable effect on the data.
This study has expanded upon the current knowl-
edge of outcome measures in LEM and demon-
strates that the 3TUG is reproducible in LEM
patients, consistently scored by observers, and has
both content and construct validity for LEM-
associated disability. The 3TUG is a practical, vali-
dated outcome measure for clinical assessment of
LEM patients that is suitable for use in the clinic, as
well as in clinical trials.
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